Vibrent Health CEO Praduman “PJ” Jain, who also serves as principal investigator of the NIH All of Us Research Program’s Participant Technology Systems Center, joined Healthcare IT News Executive Editor Mike Miliard to talk about the All of Us program, why his company is working with NIH on the initiative, how to ensuring clinical trials represent a broader cross-section of society, and what recent FDA guidance on clinical trial diversity might accomplish.
Like what you hear? Subscribe to the podcast on Apple Podcasts, Spotify or Google Play!
The National Institutes of Health’s All of Us Research Program – where it is on its journey to building a cohort of 1 million participants
Vibrent Health and how it’s working on this initiative
FDA draft guidance from this past April, on enrolling more participants from underrepresented racial and ethnic populations in the U.S. into clinical trials
Research inclusion goals in the All of Us program
How diversity is defined, and why it’s broader than race and ethnicity
How technology and digital health tools can help boost clinical trial diversity
More about this episode:
NIH All of Us program gearing up for ‘precision engagement,’ Eric Dishman says
NIH All of Us program makes more COVID-19 data available
NIH All of Us Research Program puts focus on precision nutrition
One man’s quest to rid health IT investing of systemic racial and gender bias
AWS teams with THREAD for AI-enabled clinical trials management
Integrating tech to improve clinical trial recruitment
Castor is working to democratize clinical trials
Why diversity in clinical trials is crucial
Email the writer: [email protected]
Healthcare IT News is a HIMSS publication.
Source: Read Full Article